NEW YORK – Molecular diagnostic firm DiaCarta said on Monday that its QuantiVirus SARS-CoV-2 test recently received the CE mark. The firm has also filed for Emergency Use Authorization of the test with the US Food and Drug Administration.
The company's qRT-PCR test detects viral RNA extracted from nasopharyngeal swabs, oropharyngeal swabs, and sputum. it targets three genes of SARS-CoV-2: the N, Orf1ab, and E genes.